U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Tirzepatide has quickly become one of the most talked-about medications in the weight loss space. Originally developed to treat type 2 diabetes, it has shown significant results in helping people lose ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 ...

Cipla has launched Yurpeak (tirzepatide), a once-weekly injectable for adults with obesity and type 2 diabetes. As the second ...

Ozempic has taken over our social feeds and conversations, but what happens when you stop taking it? Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have taken the world by storm, ...

Tirzepatide and semaglutide would have to drop their current net prices by 30.5% and 81.9%, respectively, to be cost-effective. Over a lifetime of use, tirzepatide could avert 45,609 obesity cases, 20 ...